Puma Biotechnology Inc logo

PBYI

Puma Biotechnology Inc

$3.13

Earnings Summary

Revenue
$45.74Mn
Net Profits
$-3.4Mn
Net Profit Margins
-7.44%

Highlights

Revenue:

Puma Biotechnology Inc’s revenue fell -53.41% since last year same period to $45.74Mn in the Q1 2022. On a quarterly growth basis, Puma Biotechnology Inc has generated -17.38% fall in its revenue since last 3-months.

Net Profits:

Puma Biotechnology Inc’s net profit fell -120.59% since last year same period to $-3.4Mn in the Q1 2022. On a quarterly growth basis, Puma Biotechnology Inc has generated -182.52% fall in its net profits since last 3-months.

Net Profit Margins:

Puma Biotechnology Inc’s net profit margin fell -144.19% since last year same period to -7.44% in the Q1 2022. On a quarterly growth basis, Puma Biotechnology Inc has generated -199.88% fall in its net profit margins since last 3-months.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the Puma Biotechnology Inc post its latest quarter earnings

EPS Estimate Current Quarter
-0.02
EPS Estimate Current Year
-0.02

Highlights

EPS Estimate Current Quarter:

Puma Biotechnology Inc’s earning per share (EPS) estimates for the current quarter stand at -0.02 - a 88.24% jump from last quarter’s estimates.

EPS Estimate Current Year:

Puma Biotechnology Inc’s earning per share (EPS) estimates for the current year stand at -0.02.

Key Ratios

Key ratios of the Puma Biotechnology Inc post its Q1 2022 earnings

Earning Per Share (EPS)
-0.08
Return on Assets (ROA)
0.03
Return on Equity (ROE)
-1.4
Dividend Per Share (DPS)
0

Highlights

Earning Per Share (EPS):

Puma Biotechnology Inc’s earning per share (EPS) fell -120% since last year same period to -0.08 in the Q1 2022. This indicates that the Puma Biotechnology Inc has generated -120% annual rate of fall in its earning per share (EPS) in the last 4 quarters.

Return on Assets (ROA):

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Puma Biotechnology Inc’s return on assets (ROA) stands at 0.03.

Earning Per Share (EPS):

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Puma Biotechnology Inc’s return on equity (ROE) stands at -1.4.

Dividend Per Share (DPS):

Puma Biotechnology Inc declared 0 dividend per share during the earnings announcement for Q1 2022.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %
2022-05-05
-0.17
-0.08
52.94%

Company Information

Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the development and commercialization of innovative products to enhance cancer care. Puma in-licenses the global development and commercialization rights to PB272 (neratinib, oral), PB272 (neratinib, intravenous) and PB357. Neratinib, oral was approved by the U.S. Food and Drug Administration in 2017 for the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer, following adjuvant trastuzumab-based therapy, and is marketed in the United States as NERLYNX® (neratinib) tablets. In February 2020, NERLYNX was also approved by the FDA in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting. NERLYNX was granted marketing authorization by the European Commission in 2018 for the extended adjuvant treatment of adult patients with early stage hormone receptor-positive HER2-overexpressed/amplified breast cancer and who are less than one year from completion of prior adjuvant trastuzumab-based therapy. NERLYNX is a registered trademark of Puma Biotechnology, Inc.

Organisation
Puma Biotechnology Inc
Employees
267
Industry
Health Technology